dapagliflozin

Dapagliflozin (BMS-512148) 是一种葡萄糖协同转运蛋白2 (SGLT2) 抑制剂，可与靶点竞争性结合。Dapagliflozin 可用于 2 型糖尿病的治疗，可以减少肾脏的葡萄糖重吸收，增加尿液中葡萄糖的排泄，从而降低血浆葡萄糖水平。

O-Desethyl Dapagliflozin (Empagliflozin-4) 是一种 SGLT2 抑制剂, IC50=33nM.

Dapagliflozin impurity is the enantiomer of Dapagliflozin, Dapagliflozin is a sodium glucose transporter 2 inhibitor.

Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport.[1] Dapagliflozin is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A9 to dapagliflozin-3-O-β-D-glucuronide, which is 2,600-fold less potent than the parent compound with regard to SGLT2 inhibition.[2]

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) 是 Dapagliflozin 1,2-propanediol, hydrate 的 S 型异构体，是竞争性葡萄糖协同转运蛋白2 抑制剂，可促进尿液中葡萄糖的排泄，可用于糖尿病的研究。它诱导 HIF1表达并减轻肾脏 IR 损伤。

Dapagliflozin D5 (BMS-512148 D5) is a deuterated form of Dapagliflozin, a competitive SGLT2 inhibitor.

Dapagliflozin-13C6 (glucitol-13C6) 是 Dapagliflozin 的 13C 的标记化合物。Dapagliflozin 的 CAS 号为 461432-26-8。Dapagliflozin竞争性的葡萄糖协同转运蛋白2 (SGLT2) 抑制剂，可促进尿液中葡萄糖的排泄，在糖尿病 (DM) 研究中具有价值。Dapagliflozin 诱导HIF1表达并减轻肾脏 IR 损伤。